

ORAL PRESENTATIONS - PROFFERED ABSTRACTS | APRIL 25 2025

Abstract CT009: SHR-A1811, a HER2-directed antibody-drug conjugate (ADC), in advanced *HER2*-mutant non-small cell lung cancer (NSCLC): Updated phase 2 results from HORIZON-Lung **FREE**

Shun Lu; Ziming Li; Yan Wang; Yuping Sun; Linlin Wang; Xingya Li; Longhua Sun; Zhiyi He; Haiyan Yang; Yongsheng Wang; Qiming Wang; Zhengbo Song; Wei Hong; Yong Wang; Guohao Xia; Yan Yu; Min Peng; Yong Song; Donglin Wang; Rui Meng; Jian Fang; Yongzhong Luo; Wenhua Liang; Sheng Hu; Zhihui Wang; Haichuan Su; Zhiyong He; Liuning Li; Wei Guo; Zhentian Liu; Qitao Yu; Yun Zhao; Runxiang Yang; Peng Chen; Yiru Wang; You Li; Lulu Yang; Wei Shi

[+ Author & Article Information](#)*Cancer Res* (2025) 85 (8_Supplement_2): CT009.<https://doi.org/10.1158/1538-7445.AM2025-CT009>

Split-Screen



Views ▾



Share ▾



Tools ▾



Versions ▾

Abstract

Background:

SHR-A1811 is a novel ADC consisting of a humanized HER2-directed monoclonal antibody, cleavable tetrapeptide-based linker, and DNA topoisomerase I inhibitor. We conducted a multicenter, open-label, phase 1/2 study to evaluate SHR-A1811 in HER2-altered NSCLC. In the registrational phase 2 portion in patients (pts) with *HER2*-mutant NSCLC, the primary endpoint of IRC-assessed ORR was met (DCO, Jun. 14, 2024). Here, we presented an updated analysis after an additional 6-mo follow-up, focusing on survival outcomes.

Methods:

Pts with advanced NSCLC and centrally confirmed *HER2* mutation, previously treated with (or intolerance to) platinum-based chemo and anti-PD-1/PD-L1 therapy, were enrolled. SHR-A1811 was administered at 4.8 mg/kg IV Q3W.

Results:

94 pts were enrolled and treated. Median prior lines of therapy was 2 (range 1-9); all received platinum-based chemo and anti-PD-1/PD-L1 therapy and 23.4% received anti-HER2 TKI. 25.5% had BM at baseline. The most common *HER2* mutation was exon 20 insertions (overall, 94.7%; A775_G776insYVMA, 72.3%). As of DCO (Dec. 14, 2024), median follow-up was 14.2 mo (range 4.7-18.2). Per IRC, ORR was 74.5% (95% CI 64.4-82.9); median DoR was 9.8 mo (95% CI 8.3-13.9). Median PFS was 11.5 mo (95% CI 9.7-15.2), with consistent benefits observed across baseline subgroups (**Table 1**). Efficacy per INV is shown in **Table 1**. Median OS was not reached; 12-mo OS rate was 88.2% (95% CI 79.8-93.3). Grade ≥ 3 TRAEs occurred in 63

[Skip to Main Content](#)

(67.0%) pts; all with incidence $\geq 5\%$ were haematological toxicities. ILD occurred in 8 (8.5%; grade 1-2, n=7; grade 3, n=1) pts. TRAEs led to dose discontinuation in 2 (2.1%) pts. There was no treatment-related death.

Conclusions:

At the updated analysis, SHR-A1811 continued to show clinically meaningful efficacy with a manageable safety profile in pts with previously treated *HER2*-mutant NSCLC, supporting it as a potential new treatment option for this population.

Table 1

Efficacy summary

	Patients (n=94)	
	IRC	INV
ORR, % (n/N; 95% CI)	74.5 (70/94; 64.4-82.9)	68.1 (64/94; 57.7-77.3)
Median DoR, mo (95% CI)	9.8 (8.3-13.9)	9.9 (7.2-11.5)
DCR, % (n/N; 95% CI)	98.9 (93/94; 94.2-100.0)	96.8 (91/94; 91.0-99.3)
Median PFS, mo (95% CI)	11.5 (9.7-15.2)	12.5 (9.9-15.1)
PFS by baseline subgroup, mo (95% CI)		
BM (n=24)	11.3 (9.5-NR)	-
No BM (n=70)	11.5 (8.5-15.2)	-
1 line of prior therapy (n=43)	9.9 (8.1-NR)	-
≥ 2 lines of prior therapy (n=51)	13.9 (9.7-16.8)	-
Prior anti-HER2 TKI (n=22)	9.7 (8.3-16.8)	-
No prior anti-HER2 TKI (n=72)	11.5 (9.9-NR)	-
A775_G776insYVMA (n=68)	15.2 (10.6-16.8)	-
Other mutations (n=26)	9.6 (7.1-11.1)	-

BM, brain metastases; DCR, disease control rate; DoR, duration of response; INV, investigator; IRC, independent review committee; NR, not reached; ORR, objective response rate; PFS, progression-free survival; TKI, tyrosine kinase inhibitor.

[Skip to Main Content](#)

Citation Format:

Shun Lu, Ziming Li, Yan Wang, Yuping Sun, Linlin Wang, Xingya Li, Longhua Sun, Zhiyi He, Haiyan Yang, Yongsheng Wang, Qiming Wang, Zhengbo Song, Wei Hong, Yong Wang, Guohao Xia, Yan Yu, Min Peng, Yong Song, Donglin Wang, Rui Meng, Jian Fang, Yongzhong Luo, Wenhua Liang, Sheng Hu, Zhihui Wang, Haichuan Su, Zhiyong He, Liuning Li, Wei Guo, Zhentian Liu, Qitao Yu, Yun Zhao, Runxiang Yang, Peng Chen, Yiru Wang, You Li, Lulu Yang, Wei Shi. SHR-A1811, a HER2-directed antibody-drug conjugate (ADC), in advanced *HER2*-mutant non-small cell lung cancer (NSCLC): Updated phase 2 results from HORIZON-Lung [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT009.

©2025 American Association for Cancer Research

Advertisement

View Metrics

Citing Articles Via

Google Scholar



Email Alerts

Article Activity Alert

[Skip to Main Content](#)

eTOC Alert

Latest News

Deploying AI to Better Suss Out HER2 Status

New Ovarian Cancer Combo Shows Wider Promise

“Brain Fog” after CAR T May Be Reversible

[View more recent articles](#) >

Breaking

PI3K Inhibitor Delays Chemotherapy Start

Drug Combo Boosts Lung Cancer Survival

Genentech, Orionis to Stick Together with Deal on Glues

[View more recent articles](#) >

Research Watch

Ferroptosis Is Induced by Lysosomal Iron Activation in Cancer Cells

Common Blood Tests Predict CAR T-cell Therapy Response in Non-Hodgkin Lymphoma

Frequent Blood Donation Influences DNMT3A-Driven Clonal Hematopoiesis

[View more recent articles](#) >

Advertisement

[Skip to Main Content](#)

Issues

News

Online First

Twitter

Online ISSN 1538-7445 Print ISSN 0008-5472

AACR Journals

- Blood Cancer
Discovery
- Cancer Discovery
- Cancer
Epidemiology,
Biomarkers &
Prevention
- Cancer Immunology
Research
- Cancer Prevention
Research

- Cancer Research
- Cancer Research
Communications
- Clinical Cancer
Research
- Molecular Cancer
Research
- Molecular Cancer
Therapeutics



- Information on
Advertising & Reprints
- Information for
Institutions/Librarians
- RSS Feeds
- Privacy Policy

Copyright © 2025 by the American Association for Cancer Research.